Immunoprecise(IPA) - 2024 Q2 - Earnings Call Transcript

Sure, Will. This is Jennifer again. I'll take that question for you. So, yes, so first of all, I think it's essential to acknowledge that these are substantial investments we've made in Talem and for the acquisition of BioStrand. And these investments, as well as the recent fundraising are at a valuation that we don't believe and may not currently reflect our intrinsic value. So first of all, I'd like to touch just a little bit then on the strategic rational behind these investments. Really both Talem and B ...